Prevera (Medroxyprogesterone Acetate) for Cyclic Pelvic Pain and Premenstrual Mastalgia
For a reproductive-age woman with cyclic pelvic pain and premenstrual mastalgia, medroxyprogesterone acetate (MPA) should be prescribed at 5-10 mg daily for 5-10 days per cycle (days 16-25), with reassessment every 3-6 months to determine continued need for therapy. 1
Dosing Schedule
For Cyclic Pelvic Pain
- Start with 5-10 mg daily for 5-10 days beginning on day 16 of the menstrual cycle 1
- The 10-day protocol (days 16-25) is more effective than the 15-day protocol for regulating menstrual cycles and stopping abnormal bleeding 2
- For pelvic congestion syndrome specifically, higher doses (30 mg daily for 6 months) have shown efficacy in reducing pain by 75% when ovarian suppression is achieved 3
- Progestin withdrawal bleeding typically occurs 3-7 days after discontinuing therapy 1
For Premenstrual Mastalgia
MPA is NOT recommended for mastalgia treatment. Despite theoretical rationale, a randomized controlled trial demonstrated that 20 mg/day MPA during the luteal phase provided no better pain relief than placebo 4. Paradoxically, depot MPA (DMPA) at contraceptive doses actually reduces mastalgia prevalence from 21% to 9% compared to controls 5, suggesting that continuous ovarian suppression—not cyclic supplementation—may be beneficial if hormonal therapy is pursued.
Contraindications (Absolute)
Before prescribing, you must exclude:
- Pregnancy (obtain pregnancy test; MPA increases risk of minor birth defects if used in first 4 months) 1
- Unusual vaginal bleeding (rule out malignancy with endometrial sampling if indicated) 1
- Current or history of breast cancer or other hormone-sensitive malignancies 1
- Active or history of thromboembolic disease (stroke, MI, DVT/PE) 1
- Active liver disease 1
- Known hypersensitivity to MPA 1
Monitoring Requirements
Initial Assessment
- Confirm diagnosis of cyclic pelvic pain etiology (endometriosis, pelvic congestion, ovulatory dysfunction)
- Exclude organic pathology through appropriate imaging/laparoscopy
- Baseline pregnancy test
- Document baseline pain severity using validated scales (VAS or numerical rating scale)
Ongoing Monitoring
- Reassess every 3-6 months to determine if treatment remains necessary 1
- Monitor for breakthrough bleeding (common side effect; occurs in significant proportion of users) 1
- Annual pelvic exam and breast exam 1
- If breakthrough bleeding persists, consider NSAIDs for 5-7 days as first-line management 6
Red Flags Requiring Immediate Evaluation
- New breast lumps
- Unusual vaginal bleeding patterns
- Sudden severe headaches
- Visual changes or speech difficulties
- Severe chest or leg pain (possible thromboembolism)
- Signs of pregnancy 1
Clinical Algorithm
- Confirm eligibility: Rule out contraindications, obtain pregnancy test
- Start low: Begin with 5 mg daily on days 16-25 of cycle 1
- Titrate if needed: Increase to 10 mg daily if inadequate response after 2-3 cycles
- Reassess at 3 months: Evaluate pain reduction using standardized scales
- Continue if effective: Maintain lowest effective dose with 3-6 month check-ins 1
- Discontinue if ineffective: If no improvement after 3 cycles, consider alternative therapies
Important Caveats
For mastalgia specifically: Do not use cyclic MPA based on high-quality evidence showing no benefit over placebo 4. If considering hormonal therapy for mastalgia, depot DMPA for continuous ovarian suppression shows more promise 5, though this is off-label for mastalgia treatment.
For pelvic pain: The evidence supports MPA effectiveness primarily when pain is related to endometriosis 7, 8 or pelvic congestion with demonstrable ovarian suppression 3. If pain persists despite adequate trial, reconsider the diagnosis.
Bone density concerns: While relevant for depot formulations with prolonged use, oral cyclic MPA at these doses and durations has minimal bone density impact 9.
Bleeding irregularities: These are the most common side effect. Counsel patients that irregular bleeding, spotting, or amenorrhea may occur and does not indicate treatment failure 1. NSAIDs for 5-7 days can manage breakthrough bleeding 6.